Cannabis Law Report

JANUARY 13, 2020

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. Key Priorities for 2020.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

Puff Puff Post

JANUARY 1, 2020

Cancer patients suffer not only from cancer, but the damaging effects of treatment. Doctors prescribe various forms of opiods to cancer patients for pain. At other times cannabis treats the pain of cancer patients better. Early studies suggest, and patients confirm, the use of cannabis i n pain management for cancer.

Treatment 64

Treatment Clinical Trials Research and Development Cannabinoids 64

Puff Puff Post

JANUARY 1, 2020

Cancer patients suffer not only from cancer, but the damaging effects of treatment. Doctors prescribe various forms of opiods to cancer patients for pain. At other times cannabis treats the pain of cancer patients better. Early studies suggest, and patients confirm, the use of cannabis i n pain management for cancer.

Treatment 40

Treatment Clinical Trials Research and Development Cannabinoids 40

Healer

DECEMBER 17, 2021

Drug interactions reported in the scientific literature most often occur at very high doses used in clinical trials of epilepsy and other conditions. Patients using warfarin need to have their blood INR level tested after adding THC-containing cannabis to their regimen. topiramate. rufinamide. zonisamide. eslicarbazepine.

CBD 98

CBD THC Conditions Medicine 98

The Joint Blog

FEBRUARY 24, 2021

This is not the first medicinal trial of its kind. Cannabis and CBD oils have often been used to reduce the effects of epilepsy and several other neurological issues, so why not Parkinson’s? Though trialing is relatively new and there is no clear scientific evidence as of yet, anecdotal evidence from patients is looking positive.

Treatment 55

Treatment Clinical Trials Collective Patients 55

Cannabis Law Report

DECEMBER 7, 2021

The search included studies through 11-May-2020. This trend is also observed in the pediatric population, where MCs are authorized in children for refractory epilepsy, especially in Dravet syndrome and Lennox-Gastaut syndrome 2. The search included published and unpublished studies through 11-May-2020.

Safety 52

Safety Cannabinoids Events Data 52

Healer

DECEMBER 17, 2021

Drug interactions reported in the scientific literature most often occur at very high doses used in clinical trials of epilepsy and other conditions.[1]. Patients using warfarin need to have their blood INR level tested after adding THC-containing cannabis to their regimen. topiramate. rufinamide. zonisamide.

CBD 52

CBD THC Conditions Medicine 52

Project CBD

FEBRUARY 28, 2023

This was somewhat less than the nearly 37% decline seen in 2020. decline from 2020. 13 Although many review authors reported inconclusive findings due to low-quality studies, they noted that evidence from human clinical trials seems to support CBD’s positive effects on nociceptive pain (i.e., million on these products.

CBD 144

CBD Seed-To-Sale Food Access 144

Cannabis Law Report

DECEMBER 23, 2021

However, regulations are constantly shifting beneath the feet of operators and their ability to serve patients depends on their capacity to navigate a changing landscape of governance. Research on the endocannabinoid system is one of the most promising avenues for new therapeutics in medicine at the moment.

Pharmaceutical 96

Pharmaceutical Clinical Trials Research and Development Cannabinoids 96

Cannabis Law Report

NOVEMBER 15, 2021

Finally, we recently acquired the worldwide rights to VRP324, which is an intranasal pharmaceutical-grade cannabidiol product candidate for the management of epilepsy in children (rare pediatric disease) and adults. FINANCIAL RESULTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2021 AND 2020. On September 9, 2021, Jeffrey A.

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Chronic Pain 52

Cannabis Law Report

SEPTEMBER 9, 2021

Medical cannabis is used for the treatment of various chronic conditions, such as Parkinson’s disease, Alzheimer’s disease, arthritis, cancer, depression, anxiety, epilepsy, and other neurological conditions. The medical end-use segment dominated the market in 2020 and will retain the leading position during the forecast years.

Recreational 95

Recreational Hemp THC Legalization 95

The Cannigma

MARCH 12, 2021

But sometimes one unintended consequence of adult-use legalization is that the market no longer caters to medical patients. So, you have this attempt to legitimize healthcare and to adopt standards, to do things in a more scientific way, and in a more credible way, for patients and for industry. It’s a non-trivial issue.

Legalization 128

Legalization Patients Education Dispensary 128

Cannabis Law Report

NOVEMBER 24, 2021

However, the nature of the government regulations and the subsequent complexity of prescribing, as well as doctors’ safety uncertainties and the stigma of the plant, remain contributing barriers to patient access. Patients can legally access medicinal cannabis through a doctor, via the TGA’s Authorised Prescribers and Special Access schemes.

Research and Development 52

Research and Development Medicine Access Media 52

Cannabis Law Report

SEPTEMBER 1, 2019

The Victorian and New South Wales Governments had both begun clinical trials of cannabis products for children with severe epilepsy and for palliative care, respectively. The clinical trials and the standard of production could lead the world.”. Around the country, the nascent industry’s march is gathering pace.

Clinical Trials 53

Clinical Trials Research and Development Medicine Cultivation 53

Cannabis Law Report

NOVEMBER 10, 2021

IND-enabling studies for Envelta are being performed under a Cooperative Research and Development Agreement (CRADA) with NCATS entered into by Virpax in August of 2020. “We In October 2021, Virpax announced that a $1.87 million contract had been signed with Recro Pharma for the development, manufacturing, and stability studies of Envelta.

Research and Development 52

Research and Development Chronic Pain Pharmaceutical Clinical Trials 52

SMPL

MAY 26, 2020

Miller spent the months after this meeting leading hundreds of CBD seminars for farmers; Dr. Kerr began informal patient surveys to track how CBD made people feel; and as he finished his book, Mr. Lee often traveled around with Mr. Laughter and Mr. Ringo’s high-CBD plants and seeds, spreading the gospel at pot shops across the West.

CBD 40

CBD Research and Development Pharmaceutical Seed-To-Sale 40

Cannabis Law Report

OCTOBER 17, 2019

Some of the potential health benefits associated with THC and CBD, with and without the high, respectively, include reducing chronic pain such as from migraines or cancer, alleviating anxiety, reducing inflammation, and helping treat conditions such as epilepsy, PTSD, and glaucoma. This is true even if the CBD comes from industrial hemp.

Law 40

Law Seed-To-Sale Hemp Recreational 40

Cannabis Law Report

DECEMBER 30, 2019

After this historically successful year, we expect to see public and political support continue to increase in 2020 as more and more states implement sensible cannabis regulatory policies. A House floor vote on HR 3884 is anticipated in 2020. FY 2020 Successful House Appropriations Advancements. Erik Altieri.

Legislation 59

Legislation Patients Access Banking 59